Interaction of Irinotecan (CPT-11) and Its Active Metabolite 7-Ethyl-10-Hydroxycamptothecin (SN-38) with Human Cytochrome P450 Enzymes
Authors:
- Nobumitsu HaniokaNHNobumitsu Hanioka
- Shogo OzawaSOShogo Ozawa
- Hideto JinnoHJHideto Jinno
- Toshiko Tanaka-KagawaTTToshiko Tanaka-Kagawa
- Tetsuji NishimuraTNTetsuji Nishimura
- Masanori AndoMAMasanori Ando
- Jun-Ichi SawadaJSJun-Ichi Sawada
- 1 April 2002
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (4) , 391-396
Abstract
The influence of pro-inflammatory cytokines on alpha class glutathione S-transferase A1 and A2 (GSTA1/A2) expression was examined in human colonic epithelial cells (Caco-2) in culture. Dose-dependent reductions in GSTA1/A2 mRNA, protein, and activity levels occurred in Caco-2 cells cultured in conditioned medium (CM) from lipopolysaccharide-stimulated murine monocyte-macrophage cells (RAW 264.7). Neutralizing anti-interleukin-1β (IL-1β) antibodies attenuated this repression of GSTA1/A2 expression by CM. Moreover, recombinant human IL-1β reduced GSTα expression at the mRNA, protein, and activity levels in a dose-related fashion. Reduction of GSTA1/A2 mRNA levels by IL-1β was attenuated by pretreatment with IL-1 receptor antagonist. GSTA1/A2 mRNA half-lives were similar in control and IL-1β-treated cells, indicating that IL-1β has no effect on mRNA stability. In reporter gene studies, IL-1β caused a dose-related reduction of luciferase activity in Caco-2 cells transfected with the full-length GSTA1 promoter-luciferase construct. Using truncated constructs, IL-1β responsiveness was mapped to a region 286 base pairs upstream to the coding region. Deletion of a hepatic nuclear factor 1 (HNF-1) site in this region abrogated the IL-1β-mediated repression of GSTA1 promoter activity. These results demonstrate that IL-1β down-regulates GSTA1/A2 expression in cultured human enterocytes by a transcriptional mechanism involving an HNF-1 site.Keywords
This publication has 27 references indexed in Scilit:
- Prediction of In Vivo Interaction Between Triazolam and Erythromycin Based on In Vitro Studies Using Human Liver Microsomes and Recombinant Human CYP3A4Pharmaceutical Research, 2000
- Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: Prediction of in vivo drug interactionsBritish Journal of Clinical Pharmacology, 2000
- Irinotecan Therapy in Adults With Recurrent or Progressive Malignant GliomaJournal of Clinical Oncology, 1999
- Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.Journal of Clinical Investigation, 1998
- Role of Cytochrome P450 Enzymes in Drug-Drug Interactions1997
- Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and InhibitorsDrug Metabolism Reviews, 1997
- P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclaturePharmacogenetics, 1996
- Mechanisms of Topoisomerase I Inhibition by Anticancer Drugs1994
- Topoisomerase I inhibitors: topotecan and irenotecanCancer Treatment Reviews, 1994
- Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodeneChemical Research in Toxicology, 1990